Vistakon Pharmaceuticals Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Buffalo NY United States (1959)
Status: Acquired by Johnson and Johnson (1981)

Organization Overview

First Clinical Trial
2005
NCT00223951
First Marketed Drug
2010
alcaftadine (Lastacaft)
First NDA Approval
2010
alcaftadine (Lastacaft)
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Vistakon Pharmaceutical

Active Ingredients

Marketed Drugs (1)

alcaftadine (Lastacaft) (2010 NDA)

Drugs in Phase 4 Trials (3)

levofloxacin (levaquin) (2 trials)

moxifloxacin (avelox) (2 trials)

timolol (blocadren) (1 trial)

Drugs in Phase 3 Trials (2)

alcaftadine (Lastacaft) (5 trials)

ketotifen (zaditor) (2 trials)

Drugs in Phase 2 Trials (1)

bimatoprost (lumigan) (1 trial)

Indications

Approved Indications


 

Conjunctivitis, Allergic

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 4)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Eye Injuries, Penetrating (Phase 4)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hypertension (Phase 4)

Ocular Hypertension (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 6